FindTrial
Sign In

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2016-001361-81-FR
Enrollment
130
Registered
2017-02-17
Start date
2017-02-10
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 19.1 Level: LLT Classification code 10036921 Term: Prostate carcinoma System Organ Class: 100000004864

Interventions

Product Name: 68Ga-HBED-CC-PSMA Pharmaceutical Form: Solution for infusion

Sponsors

INSTITUT DE CANCEROLOGIE DE L'OUEST
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 90

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Contacts

Public ContactDRCI

INSTITUT DE CANCEROLOGIE DE L'OUEST

drci@ico.unicancer.fr33240 67 97 47

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026